Single and multiple intravenous infusions with laromestrocel, an allogeneic cell therapy, is safe in patients with mild AD and may reduce the impact of cognitive decline and brain atrophy within 9 months of treatment.
- Brian G. Rash
- Kevin N. Ramdas
- Joshua M. Hare